Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
Treatment and Managem...
...to Treat...
...Endocrine Society (ES) recommends treating pos...
Bisphosphonates...
...postmenopausal women at high risk of fra...
...: In postmenopausal women with osteoporosis who...
...nosumab
...ostmenopausal women with osteoporosis...
...nopausal women with osteoporosis who are t...
3.3: In postmenopausal women with osteoporosis tak...
...aratide and Abaloparatid...
...enopausal women with osteoporosis at ver...
...In postmenopausal women with osteoporosis who...
...osozumab
...postmenopausal women with osteoporosis at ve...
...postmenopausal women with osteoporosis...
...tive Estrogen Receptor Modulato...
...In postmenopausal women with osteopor...
Menopausal Hormone Therapy and T...
...postmenopausal women at high risk of fracture and...
6.2: In postmenopausal women with os...
...citonin...
...enopausal women at high risk of fracture w...
...lcium and Vita...
...: In postmenopausal women with low BMD a...
...menopausal women at high risk of frac...
...nitoring...
...In postmenopausal women with a low BMD and...
...Algorithm for the Management of Postmenopau...